Here, we analyzed the therapeutic effects of enhanced GM3 via VPA-induced activation of St3gal5 on albuminuria and podocyte injury in streptozotocin (STZ)-induced diabetic nephropathy model mice. This evidence concerns the gene ST3GAL5 and diabetic kidney disease.